Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer research in the US is world class. With the government pulling out, its future is uncertain

2.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.

3.

Prostate cancer detection with PET CT and PET MRI is comparable.

4.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

5.

In a recent study, Kencur ginger's anti-cancer properties were discovered.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot